Lack of overt FGF21 resistance in two mouse models of obesity and insulin resistance.

Authors:
Clarence Hale
Clarence Hale
One Amgen Center Drive
Michelle M Chen
Michelle M Chen
Yale University School of Medicine
United States
Narumol Chinookoswong
Narumol Chinookoswong
One Amgen Center Dr.
Thousand Oaks | United States
Todd Hager
Todd Hager
Department of Pharmacokinetics and Drug Metabolism
Minghan Wang
Minghan Wang
University of British Columbia
Canada
Jing Xu
Jing Xu
State Key Laboratory of Medicinal Chemical Biology
China

Endocrinology 2012 Jan 8;153(1):69-80. Epub 2011 Nov 8.

Department of Metabolic Disorders, Amgen Inc., MS 29-1-A, One Amgen Center Drive, Thousand Oaks, California 91320, USA.

Circulating levels of fibroblast growth factor 21 (FGF21), a metabolic regulator of glucose, lipid, and energy homeostasis, are elevated in obese diabetic subjects, raising questions about potential FGF21 resistance. Here we report tissue expression changes in FGF21 and its receptor components, and we describe the target-organ and whole-body responses to FGF21 in ob/ob and diet-induced obese (DIO) mice. Plasma FGF21 concentrations were elevated 8- and 16-fold in DIO and ob/ob mice, respectively, paralleling a dramatic increase in hepatic FGF21 mRNA expression. Concurrently, expression levels of βKlotho, FGF receptor (FGFR)-1c, and FGFR2c were markedly down-regulated in the white adipose tissues (WAT) of ob/ob and DIO mice. However, dose-response curves of recombinant human FGF21 (rhFGF21) stimulation of ERK phosphorylation in the liver and WAT were not right shifted in disease models, although the magnitude of induction in ERK phosphorylation was partially attenuated in DIO mice. Whole-body metabolic responses were preserved in ob/ob and DIO mice, with disease models being more sensitive and responsive than lean mice to the glucose-lowering and weight-loss effects of rhFGF21. Endogenous FGF21 levels, although elevated in diseased mice, were below the half-maximal effective concentrations of rhFGF21, suggesting a state of relative deficiency. Hepatic and WAT FGF21 mRNA expression levels declined after rhFGF21 treatment in the absence of the increased expression levels of βKlotho and FGFR. We conclude that overt FGF21 resistance was not evident in the disease models, and increased hepatic FGF21 expression as a result of local metabolic changes is likely a major cause of elevated circulating FGF21 levels.

Download full-text PDF

Source
http://dx.doi.org/10.1210/en.2010-1262DOI Listing

Still can't find the full text of the article?

We can help you send a request to the authors directly.
January 2012
12 Reads

Publication Analysis

Top Keywords

dio mice
16
fgf21
13
disease models
12
expression levels
12
fgf21 resistance
12
ob/ob dio
8
fgf21 levels
8
erk phosphorylation
8
levels βklotho
8
fgf21 mrna
8
overt fgf21
8
hepatic fgf21
8
mrna expression
8
mice
7
expression
6
levels
6
dio
5
shifted disease
4
phosphorylation liver
4
liver wat
4

Similar Publications